Abstract
MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Current Pharmaceutical Design
Title:Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies
Volume: 23 Issue: 39
Author(s): Xiaohong Du, Jitai Zhang, Juping Wang*, Xiaoming Lin*Feng Ding*
Affiliation:
- Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Collaborative and Creative Center of Molecular Pathology and Personalized Medicine, Department of Pathology, Shantou University Medical College, Shantou, Guangdong 515041,China
- Department of Thoracic Surgery, The first Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000,China
- Department of Physiology, School of Basic Medical Sciences, Wenzhou Medical University, Chashan Campus, Wenzhou, Zhejiang 325035,China
Keywords: miRNA, lung cancer, biomarker, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, exosome.
Abstract: MicroRNAs (miRNAs) are small noncoding RNAs, which downregulate gene expression by repressing or degrading mRNA targets. Lung cancer (LC), together with liver and colorectal cancers are the three leading causes of cancer death worldwide, and 80% of LCs belong to non-small cell lung cancers (NSCLCs). Despite a great advancement in developing distinct and delicate tools for early diagnosis and targeted therapies over the last decade, only about 15% of the NSCLC patients eventually survived. MiRNAs are frequently dysregulated in carcinoma, including LC. Numerous lines of evidence have demonstrated various roles played by miRNAs in the development and progression of LC. In this review, we propose to summarize the current understanding of miRNAs in LC, with a particular focus on translational application of miRNAs as novel diagnostic and prognostic biomarkers and tools for treatment.
Export Options
About this article
Cite this article as:
Du Xiaohong , Zhang Jitai , Wang Juping *, Lin Xiaoming *, Ding Feng *, Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714150118
DOI https://dx.doi.org/10.2174/1381612823666170714150118 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
γ-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease
Current Topics in Medicinal Chemistry Predicting Type-I (Rate-Shift) Functional Divergence of Protein Sequences and Applications in Functional Genomics
Current Genomics Sirtuin-1 and HIV-1: An Overview
Current Drug Targets Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Therapeutic Potential of Autotaxin/Lysophospholipase D Inhibitors
Current Drug Targets PPARδ Signaling Regulates Colorectal Cancer
Current Pharmaceutical Design Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Rationale and Design of the CAN Study: an RCT of Survival after Propofol- or Sevoflurane-based Anesthesia for Cancer Surgery
Current Pharmaceutical Design Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Association of Low Vitamin D with Complications of HIV and AIDS: A literature Review
Infectious Disorders - Drug Targets Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication
Current Molecular Medicine Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
Current Cancer Drug Targets